Physician profile
Robert Israel
NPI 1841204443
$2,687.30
in general payments reported to CMS, 2019-2025
27 companies · $67.23 in 2025
The $67.23 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.28 · 2020: $299 · 2021: $859 · 2022: $793 · 2023: $546 · 2024: $41.70 · 2025: $67.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $635.96 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $608.29 | 2021-2023 | |
| Lilly USA, LLC | $228.37 | 2020-2022 | |
| Pfizer INC. | $129.87 | 2019-2022 | |
| Dexcom, INC. | $121.85 | 2021-2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $91.27 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.14 | 2021-2023 | |
| Corcept Therapeutics | $74.50 | 2021-2023 | Korlym |
| Astrazeneca Pharmaceuticals LP | $71.72 | 2020-2023 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $66.50 | 2021-2023 | Trintellix |
| Amgen INC. | $60.03 | 2021-2025 | Evenity, Prolia |
| Allergan, INC. | $59.81 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.41 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.07 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Biohaven Pharmaceutical Holding Company LTD. | $48.89 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $48.11 | 2022-2023 | Auvelity |
| Abbott Laboratories | $47.75 | 2021-2022 | |
| Astellas Pharma US INC | $32.62 | 2019 | |
| Esperion Therapeutics, INC. | $30.18 | 2021-2025 | Nexletol |
| Glaxosmithkline, LLC. | $25.38 | 2019-2023 | Shingrix |
| Janssen Pharmaceuticals, INC | $25.37 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $20.55 | 2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $17.80 | 2022 | |
| Exact Sciences Corporation | $17.54 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $16.70 | 2021 | |
| Merck Sharp & Dohme LLC | $14.40 | 2024 | Capvaxive |
| Medtronic, INC. | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Israel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.